Modalities :
What we doState-of-the-art biotechnology
centered on antibody engineering and hematopoietic stem cell gene therapy
Areas of focus
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to human health and well-being worldwide through innovative drug discovery and global commercialization.
Driven by state-of-the-art antibody technologies and hematopoietic stem cell gene therapy, our global business is focused on bone & mineral, intractable hematological diseases/hemato oncology, rare diseases.
Cutting-edge biotechnology centered on antibody engineering technology and hematopoietic stem cell gene therapy
Technology-driven drug discovery
The novel drug discovery of Kyowa Kirin is firmly
supported by the exquisite experience and
technologies in research, development and
manufacture of biologics, and by open
innovation.
This unique style of drug discovery is
what we call technology-driven drug discovery,
focused
on the key technologies below.
Main products
Pipeline
Numerous promising pharmaceutical
candidates are emerging from our
development pipelines.
They are the result of our
never-ending efforts in honing the edge of our
state-of-the-art
technologies and deliver
innovation in medical care.
Around the world
Seamless collaboration between regions
ensures timely
delivery of novel medicines
to patients around the world,
enhanced by
close ties to research partners.
Partnerships
We are open and flexible to strategic collaborations
and partnerships
with pharmaceuticals, biotech,
and academia partners.
